Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (81-90 of 179) with videos related to

Pageof 18
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
JCO Precision Oncology|January 5, 2023
<i>HRAS</i> Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell CarcinomaNiamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
Frontiers in Oncology|April 9, 2024
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma featuresHui Li, Xin Hu, Matthew S Ning, et al.
Nature Communications|December 8, 2025
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral bloodYang Xia, Yin Zhu, Sai Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Clinical Lung Cancer|April 30, 2015
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic ProfilingXiuning Le, Jason A Freed, Paul A VanderLaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLCSonia A Patel, Monique B Nilsson, Yan Yang, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Pageof 18

Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
JCO Precision Oncology|January 5, 2023
<i>HRAS</i> Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell CarcinomaNiamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
Frontiers in Oncology|April 9, 2024
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma featuresHui Li, Xin Hu, Matthew S Ning, et al.
Nature Communications|December 8, 2025
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral bloodYang Xia, Yin Zhu, Sai Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Clinical Lung Cancer|April 30, 2015
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic ProfilingXiuning Le, Jason A Freed, Paul A VanderLaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLCSonia A Patel, Monique B Nilsson, Yan Yang, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Pageof 18